At the Arab Health 2018, the largest exhibition of the Middle East in the area of medicine and health and the second largest such exhibition in the world, the management of Nativa, a Russian pharmaceutical company, signed a number of agreements with international distributors on supplying the Russian-made products to the Middle East and East Asia. The total price of agreements exceeded $1.5 million.
The agreements were signed with such major foreign players, as Monos Pharma Trade LLC, a Mongolian distributor, and H Plus Pharma, a Syrian company. In addition, the agreement for supply of medicinal products was reached with Integrated Pharma Solutions (IPS), a Lebanese company. The first supplies are scheduled for the end of 2018.
“Our Middle Eastern and Asian partners are interested primarily in high-tech drugs for the treatment of rare (orphan) diseases and in the antitumor medicines. Nativa has strong positions in these nosological niches,” said Alexander Malin, the General Director of Nativa.
This was a significant step towards implementing the export programs of Nativa.
“Due to their high quality, European standards of manufacturing and affordable prices, our medicinal products will make a worthy competition to foreign analogs in the markets of the Middle East and East Asia,” added Mr. Malin.
During the exhibition, the company signed the agreements on supplies to Syria and Mongolia, and reached preliminary understandings on supplies to Lebanon, Yemen, and Jordan.